CN106333202A - 一种大麦若叶组合物 - Google Patents
一种大麦若叶组合物 Download PDFInfo
- Publication number
- CN106333202A CN106333202A CN201610736657.3A CN201610736657A CN106333202A CN 106333202 A CN106333202 A CN 106333202A CN 201610736657 A CN201610736657 A CN 201610736657A CN 106333202 A CN106333202 A CN 106333202A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- blood sugar
- blood
- level
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 6
- 240000005979 Hordeum vulgare Species 0.000 title abstract 3
- 235000007340 Hordeum vulgare Nutrition 0.000 title abstract 3
- 239000000049 pigment Substances 0.000 claims abstract description 14
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 3
- 241001122767 Theaceae Species 0.000 claims description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 39
- 239000008280 blood Substances 0.000 abstract description 39
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 30
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 29
- 229940116269 uric acid Drugs 0.000 abstract description 29
- 235000000346 sugar Nutrition 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000003907 kidney function Effects 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 abstract 2
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 229940043357 mangiferin Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000002994 raw material Substances 0.000 description 13
- 239000009633 chimonin Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种调节人体酸碱度、降血糖、降尿酸的大麦若叶组合物，其组成物及质量百分比为：大麦若叶粉17%~52%、芒果苷1.7%~17%、茶多糖17%~34%、茶色素17%~34%；该组合物通过多种途径、多层次达到调节人体酸碱平衡、降血糖、降尿酸的作用，同时不会影响人体的肝肾功能，具有较好的安全性。长期食用，能够有效调节人体酸碱平衡，改善亚健康以及血糖高、血尿酸高等不健康症状。
Description
技术领域
本发明涉及一种调节人体酸碱平衡、降血糖、降尿酸的大麦若叶组合物。
背景技术
糖尿病是一种代谢性疾病。机体在长期高糖应激下出现各种病理生理反应，最终发展成糖尿病肾病、糖尿病血管病变等并发症。
高尿酸血症是嘌呤代谢障碍引起的代谢性疾病，内源性的嘌呤代谢紊乱导致尿酸生成过多，当机体长期处于血尿酸浓度过高和（或）在酸性环境下，尿酸可析出结晶，沉积在骨关节、 肾脏和皮下等组织，造成组织病理学改变，导致痛风性关节炎、痛风肾和痛风石等。目前治疗高尿酸血症，西医主要是依照抑制尿酸分泌、促进尿酸排泄、抗炎等原则进行治疗，但所用药物仍有一定不良反应，可造成肾、肝、功能的损害及严重皮炎等。临床研究证实，高尿酸血症与糖尿病、高血压以及高脂血症之间存在着紧密相关性，并可诱发炎性反应，加重血管内皮损伤，最终加速冠心病和肾脏损伤的进展。
医学研究表明，人体内环境的酸碱度应该在7.35～7.45之间，也就是说，我们的体液应该呈现弱碱性才能保持正常的生理功能。当人体内环境由正常的弱碱性偏离到酸性时，体内具有蛋白质属性的催化酶、与免疫力有关的抗体、调节全身功能的激素等，就会发生絮乱，造成胰岛素抵抗、酶活力下降，从而导致血糖、血脂、尿酸及各种废物堆积上升。于是，糖尿病、痛风、心血管病、肿瘤等疾病也随之形成。
由此可见，通过添加降血糖、降尿酸天然植物成分，辅以调节人体酸碱平衡的原料，可以起到协同增效的治疗效果。
目前，针对血糖高和血尿酸高的治疗药物，主要为西药以及针对某一病症的对症药，而通过解决体液酸碱性问题，从而治疗和防治血糖及血尿酸高的食品还未见报道。
发明内容
为了克服现有降血糖、降尿酸食品存在的以上缺陷和不足，本发明提供了一种调节人体酸碱平衡、降血糖、降尿酸的大麦若叶组合物；其组成物及质量百分比为大麦若叶粉17%~52%，芒果苷1.7%~17%，茶多糖17%~34%，茶色素17%~34%，所有原料的重量百分比之和为100%；该组合物能够将人体体液调整至弱碱性，排除体内代谢垃圾，恢复体内催化酶活力以及抗体、激素等，从而对血糖高、血尿酸高具有辅助治疗作用。
喝茶是我国人民的优良传统，对茶叶提取物的相关研究为实现上述目的提供了可能；研究发现，茶多糖具有显著的的降血糖作用，该作用是多途径、多因素的综合作用，药理实验证明，茶多糖通过提高机体抗氧化功能，清除体内自由基，减弱自由基对胰岛β细胞的损伤，并改善受损伤的β胰岛细胞功能，使胰岛素分泌增加，提高胰岛素敏感性，诱导葡萄糖激酶的生成，促进糖分解，使血糖下降。茶色素是从茶叶中提取的一种多酚类物质，其主要成分是茶黄素、茶红素和茶褐素。茶色素具有良好的抗高尿酸血症的作用，其对关节疼痛、关节红肿症状的改善也较明显。
芒果苷是芒果叶中的主要有效成分，它可以通过提高胰岛素细胞再生能力、胰岛素水平、胰岛素敏感性、葡萄糖利用率等机制发挥直接降糖作用。芒果苷还具有一定的排除尿酸和抑制嘌呤代谢酶的作用，其效价与治疗高尿酸血症药物苯溴马隆基本一致，但要弱于别嘌呤，且对肝肾功能均无明显不良影响。
大麦若叶是“碱性食品之王”，可帮助身体平衡酸碱、为细胞的生长提供一个健康的弱碱性体液环境。同时，大麦若叶还可以排除体内正常代谢所分解的一般酸毒，排除农药、重金属等化学毒素，是一种真正的强效排毒产品。
本发明大麦若叶组合物可以按常规剂量添加食品学上的常规辅料，制成食品学上可接受的多种剂型，如片剂、硬胶囊、固体饮料、液体饮料、袋泡茶等。
本发明原料均为常规市售试剂或按常规方法制得试剂。
本发明的优点和技术效果：
本发明组合物以大麦若叶、芒果苷、茶多糖、茶色素为功效原料，科学配伍，各组分之间发挥了协同作用，合理搭配食用辅料，可制成具有显著调节人体酸碱平衡、降血糖、降尿酸效果的片剂、硬胶囊、固体饮料、液体饮料、袋泡茶等保健品或中药制剂；该组合物通过多种途径、多层次达到调节人体酸碱平衡、降血糖、降尿酸的作用，同时不会影响人体的肝肾功能，具有较好的安全性。长期食用，能够有效调节人体酸碱平衡，改善亚健康以及血糖高、血尿酸高等不健康症状。
具体实施方式
下面通过实施例对本发明作进一步详细说明，但本发明保护范围不局限于所述内容。
实施例1：本实施例按表1配制5个物质
表1
为了更好的验证本发明的疗效，采用本实施例1-5组的原料配比制得的组合物进行临床观察研究，来进一步说明本实施例产品对调节人体酸碱平衡、降血糖、降尿酸的疗效。
实验对象：采用自愿原则，选择门诊病人60例，其中男30例，女30例，最大年龄60岁，最小年龄18岁，临床表现为高血糖。
实验方法：将60个患者分为6组，其中5组分别服用实施例1-5的物质，每天服用2次，30天为一个疗程；另外一组为空白组对照组，其未使用上述物质及其他类似降血糖产品。
收集患者治疗前后空腹血糖、餐后2小时血糖数据，比较后进行统计学分析，结果表明P＜0.05，差异具有统计学意义。治疗后，样品组和空白对照组在该两项指标的比较结果表明，P＜0.05，差异具有统计学意义。
高血糖临床诊断标准：空腹血糖超过7.0mmol/l或餐后2小时血糖超过11.1mmol/l。
实验结果：具体测试数据见表2
表2：实验前后血糖值对比表
实验结论：本实施例的组合物对降低血糖有明显的效果；实施例1（大麦若叶、芒果苷、茶多糖、茶色素复配）与实施例2-5（大麦若叶、芒果苷、茶多糖或茶色素的单一原料）治疗效果有明显差异，实施例1治疗后血糖值下降水平优于实施例2-5，取得了协同增效的技术效果。
实施例2：本实施例按表3配制5个物质
表3
为了更好的验证本发明的疗效，采用本实施例1-5组的原料配比制得的组合物进行临床观察研究，来进一步说明本实施例产品对调节人体酸碱平衡、降血糖、降尿酸的疗效。
实验对象：采用自愿原则，选择门诊病人96例，其中男48例，女48例，最大年龄60岁，最小年龄18岁，临床表现为血尿酸高于正常值，且肾功能无损害。
实验方法：本发明经6组临床验证，其中5组分别服用实施例1-5的原料物质，每天服用组合物2次，30天为一个疗程。另外一组为空白对照组，未使用上述原料物质及其他类似降尿酸产品。
于30天后取血，分离血清测定血尿酸(HUA)，比较后进行统计学分析，结果表明P＜0.05，差异具有统计学意义。治疗后，样品组和空白对照组在该两项指标的比较结果表明，P＜0.05，差异具有统计学意义。
血尿酸高临床诊断标准：男＞417μmol/L，女＞339μmol/L。
实验结果：具体测试数据见表4
表4：实验前后血尿酸值对比表
实验结论：本实施例组合物对降尿酸有明显的效果。1组（大麦若叶、芒果苷、茶色素、茶色素复配）与2-5组（大麦若叶、芒果苷、茶色素或茶色素等单一原料）治疗效果有明显差异，1组治疗后尿酸值下降水平优于2-5，取得了协同增效的技术效果。
实施例3：本实施例按表5配制5个物质
表5
为了更好的验证本发明的疗效，采用本实施例1-5组的原料配比制得的组合物进行临床观察研究，来进一步说明本实施例产品对调节人体酸碱平衡、降血糖、降尿酸的疗效。
实验对象：采用自愿原则，选择门诊病人30例，最大年龄60岁，最小年龄18岁，临床表现为血液pH值长期维持在7.35附近或低于7.35。
实验方法：本发明经6组临床验证，其中5组分别服用实施例1 -5的原料物质，每天服用组合物2次，60天为一个疗程。另外一组为空白对照组，未使用上述原料物质及其他类似调节人体酸碱平衡的产品。
每隔15天取一次股动脉血，测定血液pH值，比较后进行统计学分析，结果表明P＜0.05，差异具有统计学意义。治疗后，样品组和空白对照组在该两项指标的比较结果表明，P＜0.05，差异具有统计学意义。
临床诊断标准：人体血液pH值在7.35～7.45之间均为正常。
实验结果：具体测试数据见表6
表6：实验前后股动脉血液pH值对比表
实验结论：本实施例中大麦若叶及组合物对调节人体酸碱平衡有明显的效果。1组（大麦若叶、芒果苷、茶色素、茶色素复配）与4组（大麦若叶单一原料）治疗效果有明显差异，2、3、5组治疗效果不明显。1组治疗后血液pH值调整水平优于4组，取得了协同增效的技术效果。
Claims (1)
1.一种大麦若叶组合物，其特征在于组成物及质量百分比为：大麦若叶粉17%~52%、芒果苷1.7%~17%、茶多糖17%~34%、茶色素17%~34%。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610736657.3A CN106333202A (zh) | 2016-08-26 | 2016-08-26 | 一种大麦若叶组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610736657.3A CN106333202A (zh) | 2016-08-26 | 2016-08-26 | 一种大麦若叶组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106333202A true CN106333202A (zh) | 2017-01-18 |
Family
ID=57822289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610736657.3A Pending CN106333202A (zh) | 2016-08-26 | 2016-08-26 | 一种大麦若叶组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106333202A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108477453A (zh) * | 2018-05-02 | 2018-09-04 | 东莞市合纵食品有限公司 | 一种大麦若叶组合物及其饮料 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693730A (zh) * | 2009-10-16 | 2010-04-14 | 天津中医药大学 | 芒果叶苷及其制备方法与应用 |
| CN101919530A (zh) * | 2009-06-11 | 2010-12-22 | 天津天士力集团有限公司 | 一种茶及其制备方法 |
| CN102228111A (zh) * | 2011-06-22 | 2011-11-02 | 必恒必信(北京)投资管理有限公司 | 一种可辅助糖尿病治疗的保健茶及其制备方法 |
| CN104054891A (zh) * | 2014-06-24 | 2014-09-24 | 安徽三只松鼠电子商务有限公司 | 一种大麦若叶口香糖及其生产工艺 |
| CN104738430A (zh) * | 2015-03-06 | 2015-07-01 | 江苏振亚食品有限公司 | 一种大麦若叶青汁粉加工方法 |
| CN105055897A (zh) * | 2015-07-13 | 2015-11-18 | 陈树杰 | 一种防治糖尿病的保健茶片及其制备方法 |
| CN105055399A (zh) * | 2015-08-19 | 2015-11-18 | 西安膳方医药科技有限公司 | 一种用于糖尿病防治的天然产物组合及其应用 |
-
2016
- 2016-08-26 CN CN201610736657.3A patent/CN106333202A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919530A (zh) * | 2009-06-11 | 2010-12-22 | 天津天士力集团有限公司 | 一种茶及其制备方法 |
| CN101693730A (zh) * | 2009-10-16 | 2010-04-14 | 天津中医药大学 | 芒果叶苷及其制备方法与应用 |
| CN102228111A (zh) * | 2011-06-22 | 2011-11-02 | 必恒必信(北京)投资管理有限公司 | 一种可辅助糖尿病治疗的保健茶及其制备方法 |
| CN104054891A (zh) * | 2014-06-24 | 2014-09-24 | 安徽三只松鼠电子商务有限公司 | 一种大麦若叶口香糖及其生产工艺 |
| CN104738430A (zh) * | 2015-03-06 | 2015-07-01 | 江苏振亚食品有限公司 | 一种大麦若叶青汁粉加工方法 |
| CN105055897A (zh) * | 2015-07-13 | 2015-11-18 | 陈树杰 | 一种防治糖尿病的保健茶片及其制备方法 |
| CN105055399A (zh) * | 2015-08-19 | 2015-11-18 | 西安膳方医药科技有限公司 | 一种用于糖尿病防治的天然产物组合及其应用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108477453A (zh) * | 2018-05-02 | 2018-09-04 | 东莞市合纵食品有限公司 | 一种大麦若叶组合物及其饮料 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102670864B (zh) | 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物 | |
| CN105169203B (zh) | 一种砂仁提取物及其用途 | |
| CN102920743B (zh) | 螺旋藻在制备抗高尿酸血症和抗痛风药物或保健食品中的应用 | |
| CN107080250A (zh) | 一种辅助降血糖的组合物、饮料及其制备方法 | |
| CN107412341A (zh) | 一种含青钱柳的降糖配方及其制备方法 | |
| CN102634441B (zh) | 一种保健醋的制备方法 | |
| CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
| CN104922176B (zh) | 一种野菊花提取物的应用 | |
| CN107812193A (zh) | 一种具有α‑糖苷酶抑制活性的药物组合物及其应用 | |
| CN104688822A (zh) | 一种辅助降血糖片及制备方法 | |
| CN102526479A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
| CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
| CN101099753A (zh) | 救必应总皂苷的制备方法及应用 | |
| CN107613998A (zh) | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 | |
| CN102716135B (zh) | 羽扇豆酮在制备预防或治疗糖尿病的产品中的应用 | |
| CN100496536C (zh) | α-葡萄糖苷酶活性抑制剂 | |
| CN106333202A (zh) | 一种大麦若叶组合物 | |
| CN104027494A (zh) | 一种具有延缓衰老及保健功效的中药组合物 | |
| CN111281902A (zh) | 木姜叶柯或其活性提取物的用途 | |
| CN101829271B (zh) | 一种具有治疗糖尿病作用的中药复方及其制备方法和应用 | |
| CN102266391A (zh) | 可同时调节餐后和空腹血糖的药食同源植物提取的组合物 | |
| CN108853050A (zh) | 一种药物载体在制备抗糖尿病药物组合物中的应用 | |
| CN109381455A (zh) | 具有调节血糖、血脂及血压功能的组合物 | |
| CN106562985A (zh) | 蒙花苷的医药保健用途 | |
| CN108379455B (zh) | 一种降尿酸组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170118 |